Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TransMedics (TMDX) Income towards Parent Company (2018 - 2026)

TransMedics has reported Income towards Parent Company over the past 8 years, most recently at $18.6 million for Q4 2025.

  • For Q4 2025, Income towards Parent Company rose 165.79% year-over-year to $18.6 million; the TTM value through Dec 2025 reached $103.5 million, up 28481.22%, while the annual FY2025 figure was $1.1 million, 207.73% up from the prior year.
  • Income towards Parent Company for Q4 2025 was $18.6 million at TransMedics, down from $24.3 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $34.9 million in Q2 2025 and troughed at -$28.2 million in Q4 2024.
  • A 5-year average of $3.4 million and a median of -$1.8 million in 2023 define the central range for Income towards Parent Company.
  • Biggest five-year swings in Income towards Parent Company: crashed 242.34% in 2023 and later skyrocketed 1318.18% in 2024.
  • Year by year, Income towards Parent Company stood at $31.7 million in 2021, then crashed by 121.23% to -$6.7 million in 2022, then surged by 537.53% to $29.4 million in 2023, then crashed by 196.06% to -$28.2 million in 2024, then skyrocketed by 165.79% to $18.6 million in 2025.
  • Business Quant data shows Income towards Parent Company for TMDX at $18.6 million in Q4 2025, $24.3 million in Q3 2025, and $34.9 million in Q2 2025.